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Human papillomavirus (HPV) causes roughly 1.6% of the plus 1.6 million cases of 
cancer that are diagnosed in the United States each year. Despite the proven safety 
and efficacy of available vaccines, HPV remains the most common sexually transmitted 
infection. Underlying the high prevalence of HPV infection is the poor adherence to the 
Centers for Disease Control recommendation to vaccinate all 11- to 12-year-old males 
and females. In fact, only about 38 and 14% of eligible females and males, respectively, 
receive the complete, three-dose immunization. The many factors associated with 
missed HPV vaccination opportunities – including race, age, family income, and patient 
education – contribute to widespread disparities in vaccine completion and related health 
outcomes. Beyond patient circumstance, however, research indicates that the rigor and 
consistency of recommendation by primary care providers also plays a significant role 
in uptake of HPV immunization. Health disparities data are of vital importance to HPV 
vaccination campaigns because they can provide insight into how to address current 
problems and allocate limited resources where they are most needed. Furthermore, even 
modest gains in populations with low vaccination rates may yield great benefits because 
HPV immunization has been shown to provide herd immunity, indirect protection for 
non-immunized individuals achieved by limiting the spread of an infectious agent through 
a population. However, the impact of current HPV vaccination campaigns is hindered 
by stagnant immunization rates, which remain far below target levels despite a slow 
overall increase. Furthermore, gains in immunization are not equally distributed across 
gender, age, demographic, and socioeconomic divisions within the recommended 
group of vaccine recipients. To achieve the greatest impact, public health campaigns 
should focus on improving immunization coverage where it is weakest. They should 
also explore more subtle but potentially significant determinants of HPV vaccine initiation 
and completion, such as the attitudes of parents and healthcare providers and factors 
that exacerbate HPV-related health outcomes, including smoking and human immuno-
deficiency virus-mediated immunosuppression. Optimizing the efficacy of vaccination 
campaigns will require a health disparities approach that both identifies and remedies the 
underlying causes of population differences in HPV vaccination.
Keywords: health disparities, human papillomavirus, papillomavirus vaccines, cancer prevention and control, 
sexually transmitted diseases, herd immunity, anal cancer, cervical cancer
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iNTRODUCTiON TO HUMAN 
PAPiLLOMAviRUS, HPv-ASSOCiATeD 
CANCeRS, AND HPv vACCiNeS
The human papillomavirus (HPV) is the most prevalent sexually 
transmitted infection (STI) in the United States. Epidemiological 
calculations project that the majority of sexually active hetero-
sexual males (90%) and females (85%) will be infected with HPV 
in their lifetimes (1). HPV infection is spread by contact with 
the skin and fluids of affected genital areas and through sexual 
activity, including vaginal, anal, and oral sex (2).
Although more than 90% of HPV infections are eventually 
cleared (2), HPV can evade the immune system of some individu-
als and cause severe, long-term health problems. The infection is 
associated with significantly increased risk for genital warts and 
a several cancers, including vaginal, vulvar, penile, anal, cervical, 
and oropharyngeal cancer (2). The burden of disease attributed 
to HPV is characterized by an annual incidence of 27,000 cases 
of cancer in the United States (3), including 90% of anal cancer 
and 70% of cervical cancer cases (4–7). Among HPV-associated 
malignancies, cervical cancer is of paramount concern; each year, 
the infection is responsible for the occurrence of 12,000 new cases 
of cervical cancer and the death of 4,200 American women (3).
In the United States, the incidence of cervical cancer varies 
by factors, such as race, ethnicity, and age. Women who are of 
Hispanic or Black heritage are 1.5–2 times more likely to develop 
cervical cancer than American women from other ethnic and 
racial backgrounds (8). The average morbidity for cervical cancer 
in Hispanic women is higher than women of other ethnicities, 
but this value is nearly double in African-American women (8). 
This fact is particularly compelling because although African-
American women are less likely to develop cervical cancer than 
Hispanic women, they are more likely to die from the condition (8). 
Furthermore, recent data reveal that the rate of completion of the 
three-dose HPV vaccine series among African-American females 
actually decreased between 2013 (63.7%) and 2014 (61.6%) and 
remains lower than completion rates among Hispanic (72.8%), 
Asian (71.7%), and White (70.6%) females (9, 10). These statistics 
highlight the racial and ethnic disproportionalities of risk for 
cervical cancer among American women, and reaffirm the need 
to pay special attention to Hispanic and African-American girls 
when assessing the barriers to HPV vaccine completion.
Fortunately, protection from HPV-related STIs and cancers 
is available through immunization by one of three HPV vac-
cines that have been approved by the federal Food and Drug 
Administration (FDA). All three vaccines – Cervarix, Gardasil, 
and Gardasil 9 – are manufactured as a three-shot series admin-
istered at months 0, 1–2, and 8 (11). In general, HPV vaccination 
has been shown to be both safe and effective (12–18), although 
there are differences in the application of each vaccine. Whereas 
Cervarix protects against HPV types 6 and 11 and is recom-
mended for use only in females, Gardasil additionally protects 
against HPV types 16 and 18 (11) and is recommended for use 
in both genders (19). The extensiveness of Gardasil’s protection 
against most HPV strains has resulted in the vaccine’s use for 99% 
of HPV immunization in the United States (19). The latest HPV 
vaccine to be approved, Gardasil 9, is even more comprehensive 
and protects against serotypes 31, 33, 45, 52, and 58 in addition 
to the strains covered by Gardasil (20, 21).
ADveRSe eFFeCTS, GUiDeLiNeS, AND 
SPeCiAL CONSiDeRATiONS ReLATeD TO 
HPv iMMUNiZATiON
The risk for post-vaccine injury or illness is generally a major 
concern for parents in their willingness to consent to the immu-
nization of their children. Therefore, it is worthwhile to explore 
how the adverse effects that parents associate with HPV vac-
cination impact HPV vaccine uptake in adolescents. According 
to a Centers for Disease Control (CDC)-endorsed report by 
the Vaccine Adverse Event Reporting System (VAERS), a total 
of 25,176 adverse events were linked to HPV immunization 
between June 2006 and March 2014 (19). Of these reported cases, 
92% were classified as “non-serious” according to the following 
definition: “not involving hospitalization, prolongation of an 
existing hospitalization, permanent disability, life-threatening 
illness, or death” (19). The majority of adverse effects reported for 
both males and females include fainting, minor reactions at injec-
tions sites (e.g., pain, swelling, and itching), headache, and nausea 
(19). These findings are consistent with results from studies that 
aggregate the adverse effects associated with HPV vaccination by 
gender and age distributions (19). Taken together, these data do 
not show significant adverse effects with the administration of 
HPV vaccines.
In light of the fact that 50% of adolescents become sexually 
active at some point during high school (ages 13–18) (22), the 
CDC specifically recommends the initiation of HPV vaccination 
between the ages of 11 and 12 to allow enough time for adoles-
cents to complete the series and develop adequate immunity 
prior to HPV exposure. The advisory committee on immuniza-
tion practices (ACIP) endorses the CDC’s recommendation by 
encouraging practitioners to incorporate the HPV vaccine into 
the routine immunization schedule for adolescent girls aged 11 or 
12 years (23). As of 2009, ACIP has extended this recommenda-
tion to include boys in this age group (23). For adolescents who 
have missed the opportune window for initiating or completing 
HPV immunization, both the CDC and ACIP encourage catch-
up immunization through age 21 and 26 for males and females, 
respectively (23).
However, only 38% of females and 14% of males in the recom-
mended age group receive the complete, three-dose immuniza-
tion (19). This insufficient coverage creates dangerous holes in the 
potential for herd immunity (24–29) against HPV infection and 
related diseases. Missed opportunities for HPV immunization 
in turn jeopardize the health of both sexually active youth and, 
more pressingly, vulnerable individuals who cannot be immu-
nized (e.g., those with religious restrictions, immunodeficiency 
disorders, or vaccine-specific allergies). Organ transplant recipi-
ents on immunosuppressive drugs and immunosuppressed HIV 
patients are also of particular concern because these individuals 
are generally at increased risk for developing cancer (30–32), 
including HPV-associated malignancies (33). Furthermore, 
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immunosuppression may preclude the development of adequate 
immunity to HPV even if all three recommended vaccine doses 
are administered.
HeALTHY PeOPLe 2020 OBJeCTiveS, 
CURReNT PROGReSS, AND ONGOiNG 
DiSPARiTieS iN HPv vACCiNATiON
In the United States, the federal agency responsible for protect-
ing the health and wellbeing of citizens is the Department of 
Health and Human Services (USDHHS). In assuming the task of 
national health promotion and disease prevention, the USDHHS 
has developed a public health surveillance program called 
Healthy People 2020 (HP2020) (34). The program’s objectives 
are designed as decade benchmark values for various community 
health indicators and are determined by the following three prin-
ciples: (1) identifying the contemporary leading causes of death 
and illness by tracking the morbidity/mortality with specific 
health measures, (2) proposing evidence-based interventions for 
these conditions, and (3) evaluating the uptake and impact of 
interventions on population health (34).
Two aspects of population health that are outlined in the 
HP2020 mission include the promotion of reproductive health 
and the prevention of STIs through effective immunization (34, 
35). The rampant prevalence of HPV infection coupled with inad-
equate HPV immunization continues to pose a major threat to 
the aforementioned reproductive health goals. The HP2020 target 
is to reach 80% completion for HPV immunization in adolescent 
females by 2020, a near fivefold increase from the 2008 baseline 
of 16.6% (19, 36). In addition to improve vaccine coverage in 
female adolescents, the HP2020 program seeks to address gender 
disparities in HPV immunization by setting vaccine coverage 
objectives for adolescent males (37). It is important to note that 
males were included in the HP2020 objectives only recently, and 
thus consider the current data limitations in assessing the dispari-
ties and trends specific to HPV vaccine completion in preteen and 
adolescent boys (37). The HP2020 objectives indicate that public 
health officials recognize that neglecting to immunize young 
males will perpetuate the spread of HPV and increase the risk to 
HPV-related diseases for both males and females.
Unfortunately, improvements in HPV vaccine completion 
rates do not align with the HP2020 goal. In fact, an increase of only 
3.3% was noted for females in 2014 with little to no gains between 
2011 and 2013 (9, 10, 19). Furthermore, surveillance data of HPV 
immunization among American adolescents indicate that several 
socioeconomic and demographic factors, including gender, age, 
race, ethnicity, regionalism, and family income level (relative to 
Federal Poverty Level) influence the completion of HPV immu-
nization (38, 39). A recent report by Stokley et al. indicates that 
despite the fact that national HPV vaccine coverage has increased 
in adolescents of both genders, vaccine initiation (57 vs. 35%) and 
completion (38 vs. 14%) rates remain significantly higher among 
girls (19). In addition to gender, age plays a significant role in the 
completion of HPV immunization in both males and females; 
across all age groups (13–17), the rate of HPV immunization 
completion consistently increases with age (37, 40).
Researchers have also found alarming geographic dif-
ferences in vaccine completion rates for females, which are 
lowest in the American South, particularly in Mississippi 
(24.6%), Arkansas (23.4%), and Tennessee (20.1%) (10). 
These shortcomings are not likely to be solely due to higher 
poverty rates in the South (4), because American adolescents 
whose families earn total incomes below the federal poverty 
level have higher HPV vaccine completion rates (9, 10). The 
underlying causes for these geographic differences in HPV 
immunization completion rates remain unknown and merit 
further investigation.
PAReNTAL ATTiTUDeS TOwARD HPv 
iMMUNiZATiON
Unfortunately, there is clear evidence that parental resistance is 
a barrier to HPV vaccination for children in the recommended 
age range of 11–12  years. One study found that parents are 
increasingly hesitant about vaccinating young daughters; parents 
are three times more likely to initiate vaccination in daughters 
between ages 16 and 18 than in daughters between ages 10 and 
12 (41). Among adolescent boys of the same age group, vaccine 
initiation increases by age up to age 15 (or age 14 for 2 doses) and 
then fluctuates thereafter (41).
One reason for the reluctance in vaccinating preteens and 
younger adolescents is that parents do not want to subject their 
children to multiple shots during a single doctor visit (42). Despite 
the fact that combined vaccines have been associated with equal 
efficacy and similar adverse effects as single immunizations, par-
ents are reluctant to add the HPV immunization to the meningitis 
and TDAP vaccines that are typically demanded by elementary/
high school administrations (43). However, the bigger issue in 
convincing parents to vaccinate their preteen children seems to 
be the negative connotation associated with vaccinating young 
children against a virus that is transmitted through sexual 
contact (43). In addition to feeling, there is no need to vaccinate 
non-sexually active children against HPV, parents worry that 
discussing this risk for an STI at such a young age will influence 
their children’s attitudes toward abstinence. The assumption 
is that vaccinated adolescents may feel more protected against 
reproductive health risks, and thus initiate sexual activity at an 
earlier age (43).
The inclination to delay vaccination of young adolescents is 
worrisome because there is evidence that this often results in 
parents completely neglecting to vaccinate their children against 
HPV (42). Furthermore, clinical data indicate that HPV vaccina-
tion is most effective and long-lasting when all three doses are 
administered earlier in life. One study demonstrated that immu-
nity granted through two doses in adolescents was temporarily 
non-inferior to immunity obtained by young women immunized 
with three doses; protection against serotypes 18 and 6 faltered 
at 2 and 3  years, respectively (44). While this study does not 
prove that two doses are sufficient for long-term protection, it 
provides support for immunization during early adolescence by 
demonstrating that immunogenicity is stronger in younger vac-
cine recipients. Therefore, patient age at the time of HPV vaccine 
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initiation is likely to be an important consideration for health 
outcomes.
Although the HP2020 objectives focus on the completion of 
the full three-dose HPV vaccination series, it is important to 
understand disparities in the awareness and initiation of HPV 
vaccination as they directly influence series completion. In addi-
tion to patient age at the time of vaccine initiation, other factors 
that influence parental consent to HPV immunization of their 
children include lack of knowledge about the necessity of HPV 
immunization, concerns about safety and side effects, lack of rec-
ommendation by a healthcare professional, and absence of sexual 
activity (19, 45). Underlying these factors are two major points of 
dissonance in HPV vaccine education and communication: the 
indifference toward immunization in the parents of adolescents 
who are not sexually active and the belief of some parents that it 
is not necessary for them to vaccinate their sons.
These findings highlight the need to customize the focus of 
HPV vaccine campaigns to differences in the misconceptions 
about the reasons for vaccination of both genders. Whereas the 
focus for adolescent girls should clarify the safety and efficacy of 
HPV vaccines in the protection against HPV infection and cervi-
cal cancer, educational materials for the parents of adolescent 
boys should highlight the relevancy of HPV immunization of 
males as a means to protect both genders from HPV infection 
and the many different malignancies associated with this virus.
HeALTHCARe PROviDeR 
ReCOMMeNDATiON OF HPv 
vACCiNATiON
A handful of observational studies have been conducted to dis-
sect the underlying causes of negative parental attitudes toward 
HPV immunization. One study by the CDC revealed that lack of 
vaccine recommendation by a healthcare provider is the primary 
reason why 13 and 23% parents do not have their daughters and 
sons vaccinated (19).
Clearly, the absence of a healthcare provider’s recommendation 
of HPV vaccination is a leading cause for missed immunization 
opportunities in both genders.
Another study compared parental attitudes with vaccine uptake 
and found that the three main reasons [“poor knowledge (about 
HPV and the HPV vaccine), low perceived disease susceptibility, 
and concerns about vaccine safety”] why parents fail to immu-
nize their adolescents against HPV are tied to uncertainties that 
could be clarified by a healthcare provider (45). The same study 
established a positive correlation between vaccine uptake and a 
provider’s recommendation for immunization, but unfortunately 
revealed that less than half of the parents interviewed (228/487) 
reported discussing HPV vaccination with their physician (45). 
Furthermore, this study determines the frequency of vaccine-
specific conversations between parents and physicians differs 
mostly by race, ethnicity, and maternal education; non-blacks, 
Hispanics, and mothers with less than a high school education 
reported the least number of conversations (45).
Yet, another study cross-analyzed the concerns that prevent 
physicians from recommending vaccines with the psychosocial 
assumptions that prevent parents from immunizing their ado-
lescent daughters (42). This study reaffirms that the main reason 
why parents refuse to immunize their daughters against HPV 
is the absence of a healthcare provider’s recommendation (42). 
Other perceptions that present decisive barriers to vaccination 
in adolescent females include belief that the vaccine is optional, 
unnecessary, or even discouraged by physicians, not knowing 
enough about the vaccination, and not understanding the need 
to vaccinate girls as young as 11 years old (42). Among providers, 
the leading causes for withholding recommendations about HPV 
immunization are reluctance to give multiple shots in a single visit, 
perception of the patient’s decreased sexual activity, association 
of excessive emotional charge with discussing STI’s while parents 
are present with their children, and the prioritization of other 
health information that needs to be shared during the visit (42).
Another study specifically explored the efficacy of HPV educa-
tion by analyzing how the content, design, and distribution chan-
nels of patient education materials influences parental attitudes 
toward vaccine uptake. This study finds that although half of the 
parents prefer written material in addition to speak with their 
physicians, a quarter reported difficulty in understanding written 
material, and the majority (88%) favored verbal communica-
tion as the ideal means of obtaining vaccine information (46). 
Additional analysis of online HPV information confirms that 
parents who primarily receive HPV information from the online 
sources are more likely to resist immunizing their sons. Although 
the majority of HPV-related websites report unbiased and reli-
able information about the vaccine, half of YouTube videos on 
HPV immunization express anti-vaccine sentiments (46). These 
findings suggest that physician conversation should be the main 
vehicle for communicating accurate vaccine information, non-
verbal information should occur primarily through visual media, 
and simple written materials should be available to parents as 
optional reinforcement.
The conclusions from these studies suggest that encouraging 
physicians to be clear and consistent in recommending HPV 
vaccination can significantly increase the prevalence of favorable 
parental attitudes toward HPV immunization. More specifically, 
these recommendations should be communicated in an “ongoing 
discussion” that is prefaced with sufficient information about HPV 
and the vaccine in the two to three visits before the scheduled 
immunization (45). Establishing this ongoing discussion can be 
a valuable addition to HPV vaccine campaigns because it would 
give parents the time to develop informed decisions and share 
misconceptions about the HPV vaccine with their healthcare 
provider, who can in turn address these concerns before they 
dismiss valuable vaccination opportunities (45). Provider recom-
mendation may be especially critical in optimizing vaccine uptake 
among males, who have significantly lower HPV immunization 
rates than their female counterparts (9, 10, 47). One study shows 
that 97% of parents from a given sample identified their physi-
cians as the most-trusted authority on vaccines, and that 75% 
these parents consented to have their sons immunized against 
HPV when approached with a physician’s recommendation (46).
Given the aforementioned points about parental atti-
tudes toward the HPV vaccine, it is evident that the role of 
healthcare providers as key influencers in the uptake of HPV 
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immunization cannot be ignored in the process of redesigning 
the HPV education experience for parents. Practical measures 
for eliminating barriers and inconsistencies in the effective 
communication of HPV vaccine recommendation include 
incorporating a clear rationale for early vaccination and 
standardizing the content and distribution of patient educa-
tion material during routine pediatric visits. If physicians feel 
uncomfortable prioritizing and presenting HPV immuniza-
tion in front of younger adolescents, allied health personnel 
can be assigned to deliver this information in a private and 
sensitive manner. Another solution may be to present HPV 
vaccine information to the general patient population (with-
out targeting individual patients) in the form of making video 
PSAs, posters, and pamphlets available to patients in waiting 
rooms.
iMPACT OF COMMUNiTY-BASeD 
iNTeRveNTiONS ON HPv AwAReNeSS 
AND iMMUNiZATiON
The good news is that public health authorities are responding to 
the miscommunication of HPV and HPV vaccine education by 
creating effective campaigns that target adolescents, parents, and 
providers as key players in the uptake of HPV immunization. The 
impact of community-based health facilities is highlighted by the 
finding that despite an equal willingness to vaccinate male adoles-
cents, parents who visited community health centers for vaccines 
were 3.5 times more likely (69 vs. 20%) to have vaccinated their 
sons than those who attended hospital for the same service (46). 
These data are further nuanced by a significant difference in the 
racial distribution of patients who received vaccines from hospi-
tals (60% black) versus those who were immunized at community 
health centers (70% Latino) (46). These findings suggest that 
although community-based vaccination efforts may be a power-
ful approach in promoting HPV immunization, their success may 
depend largely on the cultural sensitivity and relevance of these 
patient education experiences (46).
The first of a few examples of community-based HPV immu-
nization campaigns that will be explored in this section is “Third 
Time’s A Charm,” a campaign launched in 2013 by the Alabama 
Department of Public Health (48). The Campaign consists of a 
30-s video PSA that challenges the main misconceptions about 
HPV immunization. The video explains that HPV vaccines 
protects both males and females against HPV-related cancers, 
emphasizes the importance of receiving all three doses, explains 
that the vaccine can be combined with routine immunizations, 
and states that the preventive service is covered by insurance (49). 
The program has instituted a successful birthday-card reminder 
system to encourage adolescents to follow-up with the second 
and third series shots, and reached a large audience by advertis-
ing the PSA video in movie theaters (49). However, one aspect of 
this campaign that should be critiqued is its reliance of feminine 
esthetics (e.g., pink color scheme, heart and handbag charm 
bracelets), which may undermine vaccine uptake in adolescent 
males by perpetuating the idea that HPV-protection is a focus for 
female health (49).
“Protect Me with 3” is a second contemporary HPV vaccine 
campaign. The program, pioneered by The Arizona Partnership 
for Immunization (TAPI), focuses on the normalization of HPV 
vaccination (i.e., eliminating the stigma that it is a vaccine for 
sexually active adolescents) by integrating it with routine vaccine 
recommendations (50). The Campaign recommends HPV vac-
cination as a third integral component of adolescent vaccination 
(“1” dose of TDAP, “2” doses of meningococcal, and “3” doses of 
HPV), and emphasizing the vaccine’s role as protection against 
HPV-related cancers (50). This approach can be valuable to other 
HPV education campaigns because it models a practical way to 
reeducate parents that (a) cervical cancer is not the only health 
risk associated with HPV and (b) males are stakeholders in the 
benefits of receiving the immunization. Another strength of 
the campaign is that it segments its target audience into teens 
and parents, and appropriately customizes patient education 
material to the assumptions and values of each group (51). By 
making HPV information accessible to teens, the “Protect Me 
with 3” program empowers adolescents to become involved in 
the decision-making process of HPV immunization. This tactic 
can be particularly instrumental in addressing the immunization 
disparities associated with maternal education because HPV edu-
cated adolescents are better prepared to clarify the misconcep-
tions that ground their parents’ resistance to HPV immunization.
“You are the Key to Cancer Prevention” is a third HPV 
immunization campaign that places emphasis on the role of 
health care providers (HCPs) as key influencers on the incidence 
of HPV-related cancers among young Americans. The program 
expands HCPs’ understanding of HPV’s burden of disease by 
speaking to both the clinical and financial implications of missed 
opportunities for HPV prevention; it quantifies the morbid-
ity and mortality of cervical cancer with compelling statistics, 
and attributes $7 billion to the costs of treating genital HPV 
among non-vaccinated American women (52). The program 
also clarifies the recent–most updated CDC recommendations 
(endorsed by the American Association of Pediatrics and ACIP) 
for HPV immunization, addresses the safety concerns previously 
associated with immunizing males, and explains the importance 
of correctly spacing the three doses (52). Furthermore, the 
program speaks to the impact of complete HPV immunization 
by highlighting that reaching 33% of the target objective has 
decreased the prevalence of cervical cancer causing HPV by 56% 
among female adolescents (52). Above all, this program provides 
HCP with a practical means of overcoming the barriers of HPV 
vaccine recommendation by providing conversation guides (e.g., 
key point checklist and Q&A dialog samples) for speaking to 
mothers (52).
CONCLUSiON
The reviewed literature has revealed that patient education is one 
of the most significant determinants of HPV vaccine uptake, and 
a leading cause for missed immunization opportunities among 
both males and females is the lack of vaccine recommendation by a 
HCP. Making sure that primary care physicians are equipped with 
the knowledge, cultural sensitivity, and practical guides to inform 
their patients about HPV immunization is essential to increase 
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the ability of parents to make informed decisions about this vac-
cine and their willingness to accept it for their children. Realizing 
that primary care physicians are often tasked with covering an 
overwhelming amount of information during physical exams, it 
may be optimal to incorporate patient-led education initiatives 
in the form of virtual media (e.g., PSAs) and take-home material 
(e.g., pamphlets, links to websites, and social media pages).
Health disparities in the HPV vaccination coverage are a seri-
ous public health concern but can be looked as an opportunity 
to make significant progress in the United States population as 
a whole. HPV vaccination should be carefully approached from 
a health disparities perspective because some disparities are not 
detectable at the level of vaccine initiation and are only evident 
when data on the completion of immunization are considered 
(53). The latest available suggest that income disparities are par-
ticularly acute, with lower immunization rates below the federal 
poverty level at every dose (1–3) in both males and females (10). 
These data are particularly concerning when considering dispari-
ties that smoking rates are much higher below the poverty level 
(54), as smoking is known to contribute the risk and exacerbation 
of malignancies resulting from HPV infection (55–59).
However, the demonstrated herd immunity effect in HPV 
vaccination (24–29) suggests that vaccine coverage need not be 
universal for effective population protection. This suggests dimin-
ishing returns as HPV vaccination coverage nears completion, but 
effective herd immunity may require high levels of immunization 
depending on the characteristics of the vaccine and infectious 
agent (60, 61). HPV vaccination rates in the United States are 
far from perfect and available data suggest that improvements in 
HPV immunization can yield tremendous public health benefits. 
An example of a country that has made impressive gains in HPV 
vaccination is Rwanda, which has achieved complete immuniza-
tion coverage since the introduction of the HPV vaccine in 2011 
(62, 63). The success of these countries demonstrates that the 
goals set by the Healthy People 2020 initiative are attainable and 
should be enthusiastically pursued.
Parallels can be drawn between modern HPV vaccination 
efforts and previous work that led to the eradication of polio 
in the United States in 1979. Similar to HPV vaccine develop-
ment, the poliovirus vaccine was also improved in a stepwise 
manner with the increasing valency of new iterations (64, 65). 
Another similarity is that there is strong evidence to support the 
safety and efficacy of both the HPV (12, 13, 20, 28) and polio-
virus vaccines (66–75), even though the extent to which herd 
immunity is responsible for their efficacy can still be debated. 
These resemblances, as well as the data and programs reviewed 
herein, offer hope that HPV vaccination programs achieve the 
same degree of success as polio vaccination. Continued emphasis 
on the successful implementation of the immunization strategies 
may 1 day lead to the global eradication of both HPV and the 
poliovirus.
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